Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection-Reference-Cited by-同舟云学术

Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection

Published:2023-02-16 Issue:2 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Negatu Dereje A.¹²^ORCID,González del Río Rubén³,Cacho-Izquierdo Mónica³^ORCID,Barros-Aguirre David³^ORCID,Lelievre Joël³,Rullas Joaquín³,Casado Patricia³,Ganapathy Uday S.¹,Zimmerman Matthew D.¹,Gengenbacher Martin¹⁴^ORCID,Dartois Véronique¹⁴^ORCID,Dick Thomas¹⁴⁵^ORCID

Affiliation:

1. Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA

2. Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia

3. Global Health Medicines R&D, GlaxoSmithKline, Tres Cantos, Madrid, Spain

4. Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA

5. Department of Microbiology and Immunology, Georgetown University, Washington, DC, USA

Abstract

The combination of the β-lactam tebipenem and the β-lactamase inhibitor avibactam shows potent bactericidal activity against Mycobacterium abscessus in vitro . Here, we report that the combination of the respective oral prodrugs tebipenem-pivoxil and avibactam ARX-1796 showed efficacy in a mouse model of M. abscessus lung infection.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01459-22

Reference31 articles.

1. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus

2. Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis

3. Trends in nontuberculous mycobacteria infection in children and young people with cystic fibrosis